This is an archive of past discussions about Radium-223. Do not edit the contents of this page. If you wish to start a new discussion or revive an old one, please do so on the current talk page.
This agent is not a first-in-class, as Sr-89 has exactly the same calcium-mimetic naturally bone-homing properties and is conceptually identical. This entire article sounds like an advertisement and should be rewritten to put this agent in its proper context. — Preceding unsigned comment added by 143.111.80.27 (talk) 18:37, 10 September 2011 (UTC)
I agree that the article is written as an advertisement and should be re-written. However Sr-89 is beta emitting and alpharadin is alpha-emitting, so they are not comparable. Alpha radiation has several advantages over beta radiation (as discussed in the article, e.g. the shorter penetration leads to less effect outside of the targeted area, i.e fewer side-effects). Apharadine may be the first alpha-emitting drug of this kind, hence first-in-class - I am not enough up-to-date in this clinical area to say. /Benzocaine (talk) 12:21, 5 April 2012 (UTC)
